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Abstract
Background: Epigenetic markings acquired in early life may have phenotypic consequences later in development through
their role in transcriptional regulation with relevance to the developmental origins of diseases including obesity. The goal of
this study was to investigate whether DNA methylation levels at birth are associated with body size later in childhood.
Principal Findings: A study design involving two birth cohorts was used to conduct transcription profiling followed by DNA
methylation analysis in peripheral blood. Gene expression analysis was undertaken in 24 individuals whose biological
samples and clinical data were collected at a mean 6 standard deviation (SD) age of 12.35 (0.95) years, the upper and lower
tertiles of body mass index (BMI) were compared with a mean (SD) BMI difference of 9.86 (2.37) kg/m2. This generated a
panel of differentially expressed genes for DNA methylation analysis which was then undertaken in cord blood DNA in 178
individuals with body composition data prospectively collected at a mean (SD) age of 9.83 (0.23) years. Twenty-nine
differentially expressed genes (.1.2-fold and p,1024) were analysed to determine DNA methylation levels at 1–3 sites per
gene. Five genes were unmethylated and DNA methylation in the remaining 24 genes was analysed using linear regression
with bootstrapping. Methylation in 9 of the 24 (37.5%) genes studied was associated with at least one index of body
composition (BMI, fat mass, lean mass, height) at age 9 years, although only one of these associations remained after
correction for multiple testing (ALPL with height, pCorrected = 0.017).
Conclusions: DNA methylation patterns in cord blood show some association with altered gene expression, body size and
composition in childhood. The observed relationship is correlative and despite suggestion of a mechanistic epigenetic link
between in utero life and later phenotype, further investigation is required to establish causality.
Citation: Relton CL, Groom A, St. Pourcain B, Sayers AE, Swan DC, et al. (2012) DNA Methylation Patterns in Cord Blood DNA and Body Size in Childhood. PLoS
ONE 7(3): e31821. doi:10.1371/journal.pone.0031821
Editor: Monica Uddin, Wayne State University, United States of America
Received June 30, 2011; Accepted January 16, 2012; Published March , 2012
Copyright:  2012 Relton et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by the Biotechnology and Biological Sciences Research Council, http://www.bbsrc.ac.uk/, (BB/F007981/1). The Preterm Birth
Growth Study was originally funded by Nutricia UK; support for the follow up studies was provided by Novo Nordisk and Special Trustees of Newcastle Hospitals.
The UK Medical Research Council, http://www.mrc.ac.uk, (Grant ref: 74882) the Wellcome Trust, http://www.wellcome.ac.uk, (Grant ref: 076467) and the University
of Bristol provide core support for the Avon Longitudinal Study of Parents and Children. This DNA methylation analysis aspect of this study was specifically funded
by Asthma UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Novo Nordisk contributed funds towards the assessment in childhood, but were not involved in the project during the original
interventions which were funded by Nutricia UK. Novo Nordisk played no role in the protocol development or analysis of the data. The authors have no relevant
conflicts of interest relating to employment, consultancy, patents, products in development or marketed products etc. This does not alter the authors’ adherence
to all the PLoS ONE policies on sharing data and materials.
* E-mail: alix.groom@ncl.ac.uk
Introduction
Environmental conditions during development in utero and early
postnatal life influence health across the lifecourse, including
diseases such as obesity, type 2 diabetes and cardiovascular disease
[1–3]. Epigenetic mechanisms, whereby DNA is modified with
downstream influences on gene regulation, may explain how such
exposures are recorded with later consequences for growth,
development and health through the lifecourse [4–7].
Epigenetic patterns, in particular DNA methylation, have been
studied in both animal models and human populations with
respect to a variety of environmental and lifestyle exposures.
Previous work has demonstrated associations between early life
exposures and subsequent epigenetic patterns in offspring;
between maternal postnatal behaviours in rats and DNA
methylation [8,9], in humans between maternal nutrition during
pregnancy and DNA methylation patterns [10] and between
exposure to famine during the peri-conceptional period and DNA
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methylation patterns 60 years later [11,12]. However, despite the
comprehensive literature linking variation in DNA methylation to
phenotypic variation in cancer or in the context of rare imprinting
disorders [13] there is comparatively little evidence to date that
variation in DNA methylation, or other epigenetic markings, are
clearly associated with common complex diseases or the
programming of such [14], although evidence is beginning to
emerge in this regard [15–21]. Studies in rodent models have
shown abnormalities of insulin secretion and action, appetite
regulation, obesity, non-alcoholic fatty liver disease, hypertension
and cardiovascular parameters following a variety of dietary
challenges during pregnancy [3,22–24] and the involvement of
epigenetic processes is commonly postulated, with emerging
empirical evidence to support this [25]. These observations have
not yet been widely extended to human populations.
In order to investigate the potential causal role of epigenetic
mechanisms linking early life exposures with later phenotype,
specifically focusing on the early life programming of obesity, we
have undertaken a study measuring methylation patterns in cord
blood DNA and interrogated their relationship with later body size
and composition. A targeted approach has been adopted whereby
genes have been selected for DNA methylation analysis based
upon their identification through gene expression analysis of
children with high or low BMI at age 11–13 years. We hypothesise
that DNA methylation patterns established in utero influence gene
regulation and subsequently body composition, and explore this in
human subjects.
The study design is summarised in Figure 1. Gene expression
analysis of peripheral blood RNA from children age 11–13 years
(from the Preterm Birth Growth Study) [26], grouped by body
mass index (BMI), was conducted and used to identify genes which
were up- or down-regulated. All genes showing evidence of
differential expression and which were represented on the Illumina
Cancer Panel I DNA methylation array were then interrogated to
establish the relationship between DNA methylation status in cord
blood and later body composition in a second cohort of 178
children from the Avon Longitudinal Study of Parents and
Children (ALSPAC) [27].
The existence of inter-individual variation in DNA methylation
makes it likely that many associations between DNA methylation
and phenotype will be identified and reported, several of which
will arise through chance and prove to be spurious. A series of
statistical analyses was therefore applied, with increasing levels of
stringency, to ensure that only robust associations were identified
and to reduce the likelihood of highlighting false positive findings.
Results
Characteristics of the study populations
Characteristics of the PTBGS and ALSPAC subjects included
in this study are shown in Table S1. The two contemporaneous
study populations did not show differences in body mass index at
age 11 years despite discordance in gestational age and birth
weight although the PTBGS children had a higher fat mass when
compared to the ALSPAC children at this age. (median [IQR];
PTBGS 14,051.2g [12,064.7], ALSPAC 10,403.8g [8,970.5],
p=0.021).
Gene expression analysis
Fourteen samples were selected for gene expression analysis and
summary details of the 2 groups (high/low BMI) are provided in
Table S2. Three hundred and forty five genes were identified as
being up-regulated and 190 genes down-regulated in children with
high BMI. Of the 514 genes showing .1.2-fold differential
expression (p,1024), 29 (5.6% of differentially expressed genes)
were represented on the Illumina GoldenGate Cancer Panel I
array with a density of coverage of 1–3 CpG sites per gene. Of
these 5 genes were dropped due to their methylation status being
.99% or ,1%, leaving 44 CpG sites in 24 genes that were taken
forward for analysis in the ALSPAC cohort.
Stringent statistical analysis of DNA methylation data
OLS regression analysis (I) resulted in many associations which
were not replicable using data derived methods of standard errors,
including robust regression techniques (II) and bootstrapping (III).
Consequently, the number of associations reduced from analysis
type I to analysis type III, although results were broadly similar
between II and III. Only CpG sites which showed consistency
across all analyses were considered to provide robust associations,
therefore we present regression estimates from the bootstrapped
analysis only (Table 1). A comparison of regression estimates from
all three approaches is provided in Tables S3, S4, S5, S6.
DNA methylation at birth is associated with body size in
childhood
We investigated the association between methylation at birth
and BMI and its components at age 9 years, including
measurements of lean mass, fat mass and height. Studying the
44 pre-selected probes corresponding to 24 candidate genes
(Tables S3, S4, S5, S6), we observed a consistent association
between methylation at CDKN1C and EPHA1 CpG sites with BMI
as well as fat mass at age 9 years (Table 1). This association was
manifest as an estimated increase of 2.08% and 0.80% increase in
BMI per 1% increase in methylation at CDKN1C and EPHA1
respectively and an increase of 5.16% and 1.84% in fat mass per
1% increase in methylation respectively. Methylation at CDKN1C
was also associated with lean mass, with an estimated 0.86%
increase in lean mass per 1% increase in methylation. However,
there was no evidence for association at either of these loci with
height. Additional associations were observed between methyla-
tion at CASP10 and BMI, methylation at HLA-DOB and NID2 and
fat mass and methylation at MMP9 and MPL and lean mass.
These and all other BMI, lean and fat mass specific findings
however do not withstand multiple testing, and a larger sample is
needed to confirm the robustness of the results. Adjustment of lean
mass for fat mass was not reported given the high degree of
colinearity of these variables due to the derivation of lean mass
from fat mass measured by DXA.
We found evidence for association of methylation at ALPL and
IRF5 with height (Table 1). For the ALPL locus, an increase in 1%
Figure 1. Overview of study design. Gene expression analysis was
conducted on RNA samples collected at age 11–13 years when children
in the Preterm Birth Growth Study (PTBGS) attended clinical assessment
which included body composition measurement. Genes highlighted as
being differentially expressed in relation to high/low BMI in this study
group were then analysed in cord blood DNA samples from the Avon
Longitudinal Study of Parents and Children (ALSPAC). Methylation
levels were then analysed in relation to later body composition
assessments carried out at 9 years in this study group.
doi:10.1371/journal.pone.0031821.g001
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methylation at birth was related to a 0.15% decrease in height at
age 9 years for an average person at an average age (within the
study cohort analysed). It is likely that the observed effects are
specifically related to height, as the effects were still present when
the model was fully adjusted for age, sex, batch, fat mass and lean
mass (adjusted estimate mean (SD) =20.07% (0.03), p=0.032).
Two CpG sites at the IRF5 locus showed association with height; a
CpG site in the promoter region and one in the first exon which
were associated with a 0.42% and 0.29% decrease in height per
1% increase in methylation respectively (Table 1). Methylation at
the two sites in this gene was correlated (rho= 0.442, p,0.001).
Conservatively assuming up to 88 independent tests for body
composition (mass and height independent analyses of 44 probes),
only the identified association with methylation of ALPL and
height withstands a correction for multiple testing (pCor-
rected = 0.017). A plot of mean methylation versus 2log10 p-value
is shown in Figure 2, indicating a relatively even distribution of
statistically significant observations in genes across high, interme-
diate and low levels of methylation (Figure 2).
The associations between increased DNA methylation, gene
expression and indices of body composition for each of the 9 genes
(10 CpG sites) showing some evidence of association between cord
blood DNA methylation and later phenotype are summarised in
Table 2.
Discussion
An association between DNA methylation status at birth and
body size in childhood was observed in 9 of the 24 (37.5%) genes
selected a priori due to evidence of their differential gene expression
in children with high BMI. This observation suggests that
variation in DNA methylation patterns at birth in multiple target
genes may influence body size in childhood. This association holds
particular relevance for the role of epigenetic factors as mediators
in early life programming of disease in later life. Genes that
demonstrate perturbed expression in children with high BMI show
signs of aberrant regulation at birth, albeit in two separate study
populations. A recent study reported an association between loci
displaying a high level of inter-individual variation in DNA
methylation and BMI in adults [17], however this study was of
elderly individuals so little can be inferred with respect to early life
programming. More recent observations report an association
between DNA methylation at a CpG site in the RXR gene
promoter in DNA extracted from umbilical cord and later
adiposity in children (aged 9 years) [18]. The findings of the
current study are in accordance with this and offer additional
support for a potential functional link between DNA methylation
at birth and later adiposity, through interrogation of genes with
perturbed gene expression profiles in children with high BMI.
The most robust observation in this study links DNA
methylation at birth in the ALPL gene with decreased height at
age 9 and this association is corroborated by clear evidence for a
biological role of alkaline phosphatase (ALPL) in bone mineral-
ization [28]. Furthermore, common polymorphisms in this gene
have been associated with reduced bone mineral density, bone
strength and skeletal size [29,30]. Thus increased methylation of
this gene could plausibly cause gene silencing leading to reduced
Table 1. Bootstrap analysis of cord blood DNA methylation as a predictor of body composition (BMI, fat mass, lean mass and
height) at age 9 years.
Gene CpG site BMI Fat mass Lean mass Height
adj age, sex, batch
adj age, sex, height,
batch
adj age, sex, height,
batch adj age, sex, batch
n Est SE p n Est SE p n Est SE p n Est SE p
Alkaline phosphatase ALPL_P 158 20.14 0.22 0.52 150 20.11 0.69 0.878 150 0.06 0.1 0.552 150 20.15 0.04 2E-04
Caspase 10 CASP10_P2 75 22.13 0.91 0.02 81 0.8 0.8 0.319 69 20.38 0.34 0.261 69 20.08 0.05 0.129
Cyclin-dependent kinase inhibitor 1C CDKN1C_P2 157 2.08 0.97 0.031 149 5.16 2.48 0.037 149 0.86 0.39 0.03 149 20.02 0.2 0.928
Ephrin type-A receptor 1 EPHA1_P 157 0.8 0.4 0.048 149 1.84 0.88 0.036 149 0.27 0.15 0.067 149 0.01 0.06 0.888
HLA class II histocompatibility antigen DO
beta chain
HLA_DOB3 158 20.31 0.24 0.187 150 20.9 0.44 0.039 150 20.06 0.11 0.618 150 0.02 0.03 0.624
Interferon regulatory factor 5 IRF5_P 156 0.75 1.05 0.471 148 2.55 2.51 0.31 148 0.6 0.47 0.204 148 20.42 0.18 0.022
Interferon regulatory factor 5 IRF5_E 157 0.5 0.73 0.498 149 2.89 1.49 0.053 149 0.09 0.3 0.757 149 20.29 0.13 0.026
Matrix metalloproteinase 9 MMP9_P 157 0.08 0.18 0.655 148 20.12 0.57 0.836 148 0.17 0.08 0.042 148 20.01 0.06 0.828
Myeloproliferative leukemia virus oncogene MPL_P 158 0.1 0.11 0.353 150 0.15 0.33 0.642 150 0.11 0.05 0.021 150 20.01 0.03 0.797
Nidogen-2 NID1_P 158 20.48 0.3 0.101 150 21.19 0.56 0.035 150 20.1 0.14 0.827 150 0 0.04 0.984
The estimate provides the magnitude and direction of effect (%) on phenotype for a 1% increase in DNA methylation at that CpG site.
doi:10.1371/journal.pone.0031821.t001
Figure 2. Distribution of methylation-phenotype associations.
Distribution of 2log10 p-values for bootstrap analysis of BMI and DNA
methylation in cord blood DNA according to mean methylation levels
at the 44 CpG sites analysed.
doi:10.1371/journal.pone.0031821.g002
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gene function manifest as reduced frame size. To our knowledge
this is the first evidence linking epigenetic variation to the
determination of height. Recent and extensive investigations into
the genetic determinants of height show clearly that this trait is the
product of many loci acting in concert [31]. Further work
exploring potential epigenetic perturbation of genes known to
influence height through their polymorphic variation, which now
number in the hundreds, may explain a further proportion of
inter-individual variation in this trait.
Previous gene expression analysis studies of adipose tissue
demonstrate marked differences in gene expression in obese
subjects when compared to individuals with normal BMI [32,33].
These observations in isolation do not allow one to dissect whether
transcriptional changes are a cause or a consequence of the obese
state. The data presented in this study extend these observations
by demonstrating that DNA methylation differences are evident at
birth in children who later develop high BMI and greater fat and
lean mass in genes that are also differentially expressed in pre-
adolescent children with high BMI. This supports the hypothesis
that, at least in some biological pathways DNA methylation and
gene expression changes might precede altered body composition
and therefore obesity. Alternatively, the observed DNA methyl-
ation changes may be non-causal biomarkers un-related to gene
expression and further studies are required to delineate this.
No association was observed between methylation status at the
loci studied and birth weight (data not shown). This observation is
in concordance with the observations of Tobi et al. who report no
association of in utero growth restriction and methylation at birth at
4 loci perturbed by prenatal famine [34]. A recent study of 12 fetal
cord blood samples however reports the converse, showing a
correlation between both gene-specific and global DNA methyl-
ation (LINE-1) and infant birth weight [35]. Birth weight only
correlates weakly with BMI at age 9 years (r = 0.127) in the whole
ALSPAC cohort of .10,000 children and the sub-group used in
this study is representative of this. Our observations suggest that
the DNA methylation levels of genes interrogated does not impact
significantly on growth in utero but that any effect on phenotype
would appear to be acting during postnatal and childhood
development.
A major component of adipogenesis is proliferation and
differentiation of adipocytes. In the current study genes associated
with cell cycle and proliferation (CDKN1C) showed evidence of
differential methylation and expression. Previous studies have
shown expression of CDKN1C to be up-regulated in omental
adipose tissue of obese adults [36]. CDKN1C is a negative
regulator of cell growth and proliferation and mutations are also
implicated in the pathogenesis of Beckwith Wiedemann Syn-
drome, characterised by pre- and post-natal overgrowth [37].
Down-regulation of CDKN1C, as well as various other imprinted
genes, has also been associated with a co-ordinated decline in
postnatal growth rate [38]. The NID2 gene, methylation of which
was observed to be inversely associated with fat mass in this study,
also plays a role in adipogenesis [39]. Ephrin type-A receptor 1
(EPHA1) has been implicated in the development of the nervous
system but is also involved in the control of insulin signalling,
which in turn plays a large role in body composition [40].
The matrix metalloproteinase family, which includes MMP9,
are known to degrade the extracellular matrix [39] and increased
levels of plasma MMP9 have been reported in both obese adults
[41] and obese children [42]. Furthermore, Feinberg et al. [17] also
identified MMP9 as a locus displaying a consistent association
between DNA methylation levels and BMI at two time points in
older adults. In the current study no association was observed
between MMP9 methylation and BMI or fat mass but a negative
correlation with height in childhood was observed.
With respect to the other genes showing evidence of an
association between DNA methylation level, body size and
composition, the biological evidence is less clear. To our
knowledge, there are no known functional connections between
CASP10, HLA-DOB or MPL and the determination of body size or
composition.
Tissue specificity and the informativeness of non-target tissues
such as peripheral blood leukocyte (PBL) DNA of methylation
patterns is an area of much debate, although the use of PBL DNA
[17,43–48] or cord blood DNA [35,49,50], is commonplace in
epidemiological studies as often this is the only source of DNA
available. We observe some overlap in the genes demonstrating
differential expression and methylation in cord blood DNA with
Table 2. A summary of the relationship between increased DNA methylation in the genes listed (at a single CpG site defined by an
Illumina GoldenGate probe), gene expression and indices of body composition.
Gene Symbol
Direction of
expression
change in high
BMI children Phenotype influenced Function"
Alkaline phosphatase ALPL Q Height Bone mineralization
Caspase 10 CASP10 r– BMI Apoptosis
Cyclin-dependent kinase inhibitor 1C CDKN1C Q BMI, Fat mass, Lean mass Negative regulator of cell proliferation
Ephrin type-A receptor 1 EPHA1 Q BMI, Fat mass Development (nervous system)
HLA class II histocompatibility
antigen DO beta chain
HLADOB3 Q Fat mass Antigen presentation
Interferon regulatory factor 5 IRF5 r– Height Cell growth, differentiation, apoptosis
Matrix metalloproteinase 9 MMP9 Q Lean mass Breakdown of extracellular matrix in tissue remodelling
Myeloproliferative leukemia virus
oncogene
MPL Q Lean mass Proliferation (bone marrow haemopoietic cells)
Nidogen-2 NID1 – Fat mass Cell interactions with extracellular matrix, adipogenesis
Brief details of the known gene function and evidence of literature pertinent to body composition and/or DNA methylation for each gene are summarised.
"As defined by GeneCards (http://www.genecards.org/).
doi:10.1371/journal.pone.0031821.t002
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previous published studies of adipose tissue. If considered at a
pathway level we observe considerable overlap in the functional
gene groups detected in cord blood DNA compared to adipose
tissue (e.g. cell proliferation, apoptosis, adipogenesis). The present
study underscores the utility of PBL DNA in defining biomarkers
of methylation status that can be applied to epidemiological
investigations to further harness information on the determinants
and consequences of epigenetic variation and its impact on
common complex diseases.
One further caveat of using DNA extracted from PBL or cord
blood DNA is the relative contributions made by respective cell
types, the ratio of which may vary for example in response to
inflammation. Epigenetic signatures differ between cell types [51],
although the overall impact of this is not considered to be
substantial [45,48]. The ‘synthesised’ longitudinal design adopted
in the current study largely overcomes this caveat, at least in
relation to establishing the relationship between methylation and
phenotype. If for example inflammation, a common co-morbidity
of obesity, were to impact upon blood cell type ratio and thereby
distort methylation measurements this would be problematic in a
cross-sectional study design. A recent study linking methylation
changes in PBL DNA to obesity in adolescents in a cross sectional
study reports exactly this; that one cannot infer causation from the
observed association between methylation and the obesity
phenotype [52]. Methylation analysis conducted at birth many
years before the development of the phenotype overcomes this
problem of an inability to exclude reverse causation. A further
potential limitation is that the cord blood DNA samples used in
this study were not selected at random but on the presence/
absence of a particular prenatal exposure and postnatal pheno-
type. These variables were however not correlated with BMI and
the distribution of the variables included in the current study was
representative of the ALSPAC cohort.
Data analysis was initially based upon OLS linear regression,
which has limitations when applied to DNA methylation data. The
skewed distribution of methylation data results in heteroskedastic
residuals which violate the assumptions required for hypothesis
testing, the high degree of co-linearity between the exposures of
interest and large leverage exerted by outliers due to the small
sample size require that data interpretation is approached with
caution. To this end we undertook stringent statistical tests
including robust regression and bootstrapping. The number of
associations falling below the standard statistical threshold of
p,0.05 diminished as the level of stringency increased (Tables S3,
S4, S5, S6). As both robust and bootstrapping methods provided
overall consistent results, our findings suggest that robust
techniques might be a valuable tool for high-throughput screening
which can then be followed up by more computationally intensive
and time-consuming bootstrapping.
A key question remaining is what factors determine the
observed inter-individual variation in DNA methylation observed
in cord blood DNA? A recent study of methylation patterns in
DNA from twins from multiple tissue sources, including cord
blood DNA, highlighted a large degree of variation in methylation
even between MZ twins [50]. This suggests that the maternal in
utero environment, including placentation and nutrient supply, may
have an important influence on the neonatal epigenome. In a
study of DNA methylation in maternal infant pairs Kile et al [49]
found variable levels of correlation between methylation patterns
of mothers and their offspring, indicative of some level of
environmental contribution to this discordance. Many prenatal
exposures have been linked to variation in DNA methylation
including smoking, depression [53] and under- or over-nutrition
[10,11,54,55]. Folate exposure in utero has been implicated in the
determination of spinal bone mineral density at age 9 years in the
ALSPAC cohort [56,57] which could in turn plausibly impact
upon attained height. However, an assessment of the relationship
between maternal folate intake during pregnancy, MTHFR
genotype and body fat at age 9 years in this cohort showing no
association between these factors indicates that folate exposure in
utero is unlikely to explain the associations observed between cord
blood methylation and fat mass in the current study [58].
A further and extremely relevant potential contributor to inter-
individual variation in methylation at birth is the genetic
determination of DNA methylation patterns. Variation in gene
expression arising from allele-specific DNA methylation is well
documented [59–61]. Cis (locally) acting genetic variation might
determine DNA methylation levels and explain some of the inter-
individual variation in methylation levels at birth. These changes
would be expected to be stable over time and could not strictly be
considered as ‘programmed’ events, rather inherited phenomena.
The search for determinants of methylation variation at birth
should include both genetic and environmental factors at play
during the in utero period.
The current study has a number of limitations; the Illumina
Cancer Panel I array was used to derive quantitative measures of
gene-specific DNA methylation. This array only contained a
fraction (29/514, 5.6%) of those genes observed to be differentially
expressed in our high vs low BMI analysis. Furthermore, it is
biased heavily towards tumour suppressor genes, oncogenes, DNA
repair genes, cell cycle control, apoptosis and differentiation genes,
X-linked and imprinted genes. This bias was overcome to a degree
by the targeted approach and only using data from those genes
implicated in the determination of body composition. Due to the
technology employed, the reported associations rely on a few
‘representative’ CpG sites for each gene interrogated. A more
comprehensive analysis of the gene regions of interest is required
to gain a detailed understanding of the relationship between DNA
methylation, gene regulation and phenotype.
As with all studies of this nature, multiple testing limits the
robustness of the inferences that can be made about the observed
associations. By applying robust statistical approaches we consider
that we have minimised the potential for false positives, however
further studies are required to establish the true validity of our
observations. In addition to replication of the reported observa-
tions in other cohorts, further investigation of temporal variation
in DNA methylation patterns from birth across childhood would
be highly informative, together with examination of their
relationship with developmental trajectories of body composition
traits. The use of novel approaches for strengthening causal
inference could also be usefully adopted [62–64]. Future studies
should also include the analysis of DNA methylation using other
methodological approaches to quantify DNA methylation, in
particular the fine mapping of DNA methylation and DNA
sequence variation across the genes identified in this study.
Materials and Methods
Study populations
Ethical approval was obtained from the ALSPAC Law and
Ethics Committee and Local Research Ethics Committees in
accordance with the guidelines of The Declaration of Helsinki.
Written informed consent was obtained for all participants in the
study.
Preterm Birth Growth Study (PTBGS). Healthy preterm
infants (#34 weeks gestation) were recruited from the Special Care
Baby Unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK
[26], and were followed up intensively through childhood. Clinical
Cord Blood Methylation and Body Composition Size
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assessment including anthropometric and biochemical markers
was undertaken at 11–13 years of age when blood samples were
taken for DNA and RNA analysis. Of the original study cohort
24/83 individuals contributed to this study.
Avon Longitudinal Study of Parents and Children
(ALSPAC). Pregnant women from the Avon area in the South
West of England whose expected dates of delivery were between
April 1991 and December 1992 were invited to take part in the
study, which was successful in recruiting over 14,000 pregnancies
in this time period. ALSPAC is a prospective study and the
extensive data collected during pregnancy and throughout
childhood is described in detail elsewhere (http://www.alspac.
bristol.ac.uk) [27]. Data pertaining to body composition at 9 years
of age and relevant covariates were provided for use in this study.
DNA extracted from cord blood was used for DNA methylation
analysis (n = 178). Samples were selected as part of a prior study
according to use (or not) of paracetemol during pregnancy and the
presence/absence of asthma at age 91 months of age.
Summary details of the two study populations are provided in
Table S1.
RNA and DNA isolation
PTBGS. 2.5 ml of blood were drawn into a PAXgeneTM
Blood RNA tube (PreAnalytiX QIAGEN GmbH), incubated at
room temperature for 2 hours and then stored at 270uC until
extracted. Total RNA was extracted from whole blood using the
PAXgeneTM Blood RNA System Kit following the manufacturer’s
instructions. RNA Integrity Number (RIN) was assessed using
RNA Nano 6000 chips run on an Agilent 2100 Bioanalyzer
(Agilent Technologies, Inc., Palo Alto, California, USA) and
concentration determined using a NanoDropTM ND-1000
spectrophotometer (NanoDrop Technologies, Thermo Fisher
Scientific Inc., Waltham, MA, USA). Blood drawn into EDTA
was used for DNA extraction using QIAamp DNA blood midi kit
(Qiagen, Crawley, UK) following the manufacturer’s protocol.
ALSPAC. DNA extraction applied standard phenol-
chloroform extraction methods. DNA was re-suspended in
2 mM Tris and stored at 280uC.
Gene expression analysis
Individuals were selected from the PTBGS who participated in
a follow-up clinical examination of cardiometabolic traits during
2007–2008. Of the 24 subjects analysed, subjects passing QC
representing the highest (n = 7) and lowest (n = 7) tertiles of
distribution of BMI were compared; mean difference [SD] in BMI
was 9.86 [2.37] kg/m2. Summary details of the two groups are
provided in Table S2. No differences in height were evident
between the two groups but they were, as expected, significantly
discordant in weight, BMI and fat mass (p,0.002). RNA samples
were sent to ServiceXS (Leiden, The Netherlands) for globin
reduction, labelling, hybridization to Human NuGO-Hs1a520180
GeneChip arrays (covering 23,941 probes) and scanning of the
arrays. Globin reduction was performed using GeneChipH
Globin-Reduction kit (PreAnalytiX QIAGEN GmbH, Affymetrix
Inc., Santa Clara, California) according to the manufacturer’s
instructions (Mat. No. 1029528) using Peptide Nucleic Acid (PNA)
oligonucleotides complementary to human globin mRNA tran-
scripts (PNA; GR PNA-L G2001 Panagene Inc., Korea) and
Globin-Reduction RNA controls (No. 900586, PreAnalytiX
QIAGEN GmbH, Affymetrix Inc., Santa Clara, California).
Human NuGO-Hs1a520180 GeneChip CEL files were normal-
ised in BioConductor (http://genomebiology.com/2004/5/10/
R80/) using the GCRMA package. Genes with differential
expression between BMI groups were identified with the
RankProd package (,0.05 with 100 permutations of the class
labels) (http://bioinformatics.oxfordjournals.org/content/22/22/
2825.full). Annotations were attached to probe sets from the
nugohs1a520180.db library (http://www.bioconductor.org/help/
biocviews/2.6/data/annotation/html/nugohs1a520180.db.html).
Raw and normalised data from the experiment was deposited in
GEO (http://www.ncbi.nlm.nih.gov/geo/) with accession num-
ber GSE22013.
DNA methylation analysis
500 ng genomic DNA was treated with sodium bisulphite to
convert unmethylated cytosine to uracil using the EZ-96 DNA
Methylation KitTM (Zymo Research, Cambridge Biosciences, UK)
according to the manufacturer’s recommendations. Site-specific
CpG methylation was analysed using 5 ml (at 50 ng/ml) bisulphite
treated DNA using the GoldenGateH Cancer Panel I Array
(Illumina Inc, USA) and the GoldenGateH Assay Kit with UDG
on the Sentrix Universal-96 Array matrix v7A. This panel covers
1505 CpG sites selected from 807 genes, with a minimum of 719
genes overlapping with the expression array. The analysis was
performed with background normalisation across two sample
plates (batches) comprised of 96 samples each. The assay failed for
4 of the 1505 CpG sites. Arrays were imaged using a BeadArray
scanner and image processing and intensity data extracted using
Illumina BeadStudio v3.2, methylation module v3.2.5 custom
software. The level of methylation at a given CpG site was
determined by comparing the proportion of methylated to
unmethylated signal (expressed as a beta score, 0–1). Four samples
were assayed in duplicate in plate 1.
Indices of body composition
PTBGS. Children were measured wearing a light hospital
gown. Weight (to the nearest 0.1 kg) and height (to the nearest
0.1 cm) were measured using standard procedures, calibrated
weighing scales (Tanita, Arlington Heights, Illinois) and a
Harpenden stadiometer (Holtain Crosswell, Dyfed), and BMI
(kg/m2) calculated. Fat and lean mass were assessed using total
body scan mode on a GE Lunar iDXA machine and software
version v11.
ALSPAC. Height was measured to the nearest 0.1 cm using a
Harpenden stadiometer (Holtain Crosswell, Dyfed) and weight
while wearing underwear was measured to the nearest 50 g using
Tanita body fat analyser (model TBF 305, Tanita, Arlington
Heights, Illinois). Fat mass and lean mass were assessed by whole
body dual energy X-ray absorptiometry (DXA) (Prodigy scanner,
Lunar Radiation Corp, Madison, Wisconsin, US).
Data analysis
DNA methylation status in 178 cord blood DNA samples from
the ALSPAC cohort was analysed for a total of 54 CpG sites in 29
genes. Where fewer than n= 178 were included in the analyses,
this was due to missing phenotype data or poor call rates for
particular probes. Distribution of DNA methylation at each CpG
site was defined and those sites that were either fully methylated
(mean.0.99) or fully un-methylated (mean,0.01) or with .25%
samples with methylation values = 0 were dropped from the data
set (10 CpG sites dropped, leaving 24 genes and 44 CpG sites
included in remaining analysis). Percentage DNA methylation
levels at the remaining 44 CpG sites were analysed to assess the
relationship between methylation level and BMI, fat mass (g), lean
mass (g) and height (cm) at age 9 years. BMI, fat and lean mass
were log-transformed (natural logarithm) as they were not
normally distributed (in agreement with numerous other studies
where these variables commonly show a positively skewed
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distribution [65]). We selected several complementary analysis
methods with increasing levels of robustness towards violations of
normality, outlier effects and heteroskedasticity given the moder-
ate sample numbers available for analysis (n,150) in the present
study. Specifically, we performed (I) ordinary least squared (OLS)
regression and (II) robust regression [66], followed by (III) a non-
parametric bootstrapping of the OLS model (I). Adjustments were
made for age at clinic attendance (in months) and sex in all models
due to their potential confounding influence on DNA methylation
and outcome measures (i.e. BMI, height, lean and fat mass).
Sample batch (plate) was also included as a covariate in all models
due to its potential to cause substantial variation and bias in the
DNA methylation data. Finally, height was included as a covariate
in models assessing lean mass and fat mass due to its strong
influence on these outcome measures. Further adjustment for
height, lean mass and fat mass were made depending on the
outcome variable being considered. Data were analysed using the
statistical software package STATA (version 10.0) (Stata Corp,
College Station, TX) and the R software (version 2.12.1).
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(DOC)
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(DOC)
Table S3 Increase in % BMI for 1% increase in
methylation. Adjusted for age, sex and inter-plate variation.
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